![Klaus Breiner](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Klaus Breiner
Directeur/Membre du Conseil chez Orthocon, Inc.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
John Pacifico | M | - |
Orthocon, Inc.
![]() Orthocon, Inc. Medical SpecialtiesHealth Technology Orthocon, Inc. designs, develops, and markets medical implantable devices. It provides implantable products designed to stop bone bleeding. The company was founded in 2005 and is headquartered in Irvington, NY. | 17 ans |
Ruedger Rubbert | M | 65 |
Natural Dental Implants AG
![]() Natural Dental Implants AG Medical SpecialtiesHealth Technology Natural Dental Implants AG provides dental technology products and services. The firm specialized in the development of Replicate, a non-surgical tooth replacement system designed to alternative preserve alveolar bone and adjacent teeth. It offers an alternative solutions to traditional dental implants and three unit dental bridges, with focus on three-dimensional image and impression, natural healing, and temporary and permanent crown features. The company was founded by Ruedger Rubbert and Lea Ellermeier Nesbit in 2009 and is headquartered in Berlin, Germany. | 15 ans |
Ernst-Ulrich Berndt | M | 70 |
Natural Dental Implants AG
![]() Natural Dental Implants AG Medical SpecialtiesHealth Technology Natural Dental Implants AG provides dental technology products and services. The firm specialized in the development of Replicate, a non-surgical tooth replacement system designed to alternative preserve alveolar bone and adjacent teeth. It offers an alternative solutions to traditional dental implants and three unit dental bridges, with focus on three-dimensional image and impression, natural healing, and temporary and permanent crown features. The company was founded by Ruedger Rubbert and Lea Ellermeier Nesbit in 2009 and is headquartered in Berlin, Germany. | 17 ans |
Anders Hinsby | M | 51 |
Vico Therapeutics BV
![]() Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | 4 ans |
Luc Dochez | M | 49 |
Vico Therapeutics BV
![]() Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | 5 ans |
Richard L. Kronenthal | M | - |
Orthocon, Inc.
![]() Orthocon, Inc. Medical SpecialtiesHealth Technology Orthocon, Inc. designs, develops, and markets medical implantable devices. It provides implantable products designed to stop bone bleeding. The company was founded in 2005 and is headquartered in Irvington, NY. | 19 ans |
Erik van den Berg | M | 51 |
AM-Pharma Holding BV
![]() AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands.
Tridek-One Therapeutics SAS
![]() Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | - |
Martin C. Münchbach | M | 54 |
Bellevue Asset Management (Venture Capital)
![]() Bellevue Asset Management (Venture Capital) Investment ManagersFinance Bellevue Asset Management (Venture Capital) is the venture capital arm of Bellevue Asset Management AG, a subsidiary of Bellevue Group AG (SW: BBN) headquartered in Zurich, Switzerland. The firm was founded in 1993.
Pureos Partners AG
![]() Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | 20 ans |
Lea Ellermeier Nesbit | F | - |
Natural Dental Implants AG
![]() Natural Dental Implants AG Medical SpecialtiesHealth Technology Natural Dental Implants AG provides dental technology products and services. The firm specialized in the development of Replicate, a non-surgical tooth replacement system designed to alternative preserve alveolar bone and adjacent teeth. It offers an alternative solutions to traditional dental implants and three unit dental bridges, with focus on three-dimensional image and impression, natural healing, and temporary and permanent crown features. The company was founded by Ruedger Rubbert and Lea Ellermeier Nesbit in 2009 and is headquartered in Berlin, Germany. | 15 ans |
Josh Mandel-Brehm | M | 41 |
Vico Therapeutics BV
![]() Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | 5 ans |
Rémi Droller | M | 48 |
AM-Pharma Holding BV
![]() AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands.
Vico Therapeutics BV
![]() Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | - |
Giuseppina Caligiuri | M | - |
Tridek-One Therapeutics SAS
![]() Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | 6 ans |
Ximing Ding | M | - |
Pureos Partners AG
![]() Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | 6 ans |
Alan Levy | M | 86 |
Orthocon, Inc.
![]() Orthocon, Inc. Medical SpecialtiesHealth Technology Orthocon, Inc. designs, develops, and markets medical implantable devices. It provides implantable products designed to stop bone bleeding. The company was founded in 2005 and is headquartered in Irvington, NY. | - |
Benoit Barteau | M | - |
Tridek-One Therapeutics SAS
![]() Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | - |
Laurence de Schoulepnikoff | F | - |
Tridek-One Therapeutics SAS
![]() Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | - |
Juliane Bernholz | M | - |
AM-Pharma Holding BV
![]() AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | 5 ans |
Rita Jain | M | 62 |
AM-Pharma Holding BV
![]() AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | 4 ans |
Anne Bechet | F | - |
Vico Therapeutics BV
![]() Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | 5 ans |
Ravindra Mehta | M | - |
AM-Pharma Holding BV
![]() AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | - |
Micah Mackison | M | - |
Vico Therapeutics BV
![]() Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | 2 ans |
Patrick Honoré | M | - |
AM-Pharma Holding BV
![]() AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | - |
Felice Verduyn-van Weegen | F | - |
Vico Therapeutics BV
![]() Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | 5 ans |
James Lafferty | M | - |
Natural Dental Implants AG
![]() Natural Dental Implants AG Medical SpecialtiesHealth Technology Natural Dental Implants AG provides dental technology products and services. The firm specialized in the development of Replicate, a non-surgical tooth replacement system designed to alternative preserve alveolar bone and adjacent teeth. It offers an alternative solutions to traditional dental implants and three unit dental bridges, with focus on three-dimensional image and impression, natural healing, and temporary and permanent crown features. The company was founded by Ruedger Rubbert and Lea Ellermeier Nesbit in 2009 and is headquartered in Berlin, Germany. | - |
Rao S. Bezwada | M | - |
Orthocon, Inc.
![]() Orthocon, Inc. Medical SpecialtiesHealth Technology Orthocon, Inc. designs, develops, and markets medical implantable devices. It provides implantable products designed to stop bone bleeding. The company was founded in 2005 and is headquartered in Irvington, NY. | - |
Fraser Murray | M | 53 |
Tridek-One Therapeutics SAS
![]() Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | - |
Allen Barbieri | M | 65 |
Natural Dental Implants AG
![]() Natural Dental Implants AG Medical SpecialtiesHealth Technology Natural Dental Implants AG provides dental technology products and services. The firm specialized in the development of Replicate, a non-surgical tooth replacement system designed to alternative preserve alveolar bone and adjacent teeth. It offers an alternative solutions to traditional dental implants and three unit dental bridges, with focus on three-dimensional image and impression, natural healing, and temporary and permanent crown features. The company was founded by Ruedger Rubbert and Lea Ellermeier Nesbit in 2009 and is headquartered in Berlin, Germany. | - |
Ashok Dhanrajgir | M | - |
AM-Pharma Holding BV
![]() AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | - |
Silvia Noiman | M | 68 |
Vico Therapeutics BV
![]() Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | 4 ans |
Joël Jean-Mairet | M | 52 |
AM-Pharma Holding BV
![]() AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | - |
Richard G. Morrison | M | 87 |
The University of North Carolina at Charlotte
| 29 ans |
Jan N. Lessem | M | - |
Orthocon, Inc.
![]() Orthocon, Inc. Medical SpecialtiesHealth Technology Orthocon, Inc. designs, develops, and markets medical implantable devices. It provides implantable products designed to stop bone bleeding. The company was founded in 2005 and is headquartered in Irvington, NY. | 12 ans |
Martijn Kleijwegt | M | 69 |
Vico Therapeutics BV
![]() Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | - |
Joyce Tsang | M | 57 |
Orthocon, Inc.
![]() Orthocon, Inc. Medical SpecialtiesHealth Technology Orthocon, Inc. designs, develops, and markets medical implantable devices. It provides implantable products designed to stop bone bleeding. The company was founded in 2005 and is headquartered in Irvington, NY. | 15 ans |
Friedrich Riemeier | M | - |
Natural Dental Implants AG
![]() Natural Dental Implants AG Medical SpecialtiesHealth Technology Natural Dental Implants AG provides dental technology products and services. The firm specialized in the development of Replicate, a non-surgical tooth replacement system designed to alternative preserve alveolar bone and adjacent teeth. It offers an alternative solutions to traditional dental implants and three unit dental bridges, with focus on three-dimensional image and impression, natural healing, and temporary and permanent crown features. The company was founded by Ruedger Rubbert and Lea Ellermeier Nesbit in 2009 and is headquartered in Berlin, Germany. | - |
Alain Huriez | M | 62 |
Tridek-One Therapeutics SAS
![]() Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | - |
Russell Greig | M | 71 |
AM-Pharma Holding BV
![]() AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | - |
Amy Schulman | F | 63 |
Vico Therapeutics BV
![]() Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | 4 ans |
Geert-Jan Mulder | M | 58 |
AM-Pharma Holding BV
![]() AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | - |
Roger Bendisch | M | 65 |
Natural Dental Implants AG
![]() Natural Dental Implants AG Medical SpecialtiesHealth Technology Natural Dental Implants AG provides dental technology products and services. The firm specialized in the development of Replicate, a non-surgical tooth replacement system designed to alternative preserve alveolar bone and adjacent teeth. It offers an alternative solutions to traditional dental implants and three unit dental bridges, with focus on three-dimensional image and impression, natural healing, and temporary and permanent crown features. The company was founded by Ruedger Rubbert and Lea Ellermeier Nesbit in 2009 and is headquartered in Berlin, Germany. | - |
Edwin de Graaf | M | - |
AM-Pharma Holding BV
![]() AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | - |
Gerald Glasauer | M | 55 |
Natural Dental Implants AG
![]() Natural Dental Implants AG Medical SpecialtiesHealth Technology Natural Dental Implants AG provides dental technology products and services. The firm specialized in the development of Replicate, a non-surgical tooth replacement system designed to alternative preserve alveolar bone and adjacent teeth. It offers an alternative solutions to traditional dental implants and three unit dental bridges, with focus on three-dimensional image and impression, natural healing, and temporary and permanent crown features. The company was founded by Ruedger Rubbert and Lea Ellermeier Nesbit in 2009 and is headquartered in Berlin, Germany. | - |
Dominik Escher | M | - |
Pureos Partners AG
![]() Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | 7 ans |
Guido Magni | M | 70 |
AM-Pharma Holding BV
![]() AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | - |
David Hart | M | 47 |
Orthocon, Inc.
![]() Orthocon, Inc. Medical SpecialtiesHealth Technology Orthocon, Inc. designs, develops, and markets medical implantable devices. It provides implantable products designed to stop bone bleeding. The company was founded in 2005 and is headquartered in Irvington, NY. | 12 ans |
Gambillara Fonck Veronica | M | - |
Pureos Partners AG
![]() Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | 2 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Stephen Hall | M | 73 |
Orthocon, Inc.
![]() Orthocon, Inc. Medical SpecialtiesHealth Technology Orthocon, Inc. designs, develops, and markets medical implantable devices. It provides implantable products designed to stop bone bleeding. The company was founded in 2005 and is headquartered in Irvington, NY. | 1 ans |
Seth A. Rudnick | M | 75 |
Orthocon, Inc.
![]() Orthocon, Inc. Medical SpecialtiesHealth Technology Orthocon, Inc. designs, develops, and markets medical implantable devices. It provides implantable products designed to stop bone bleeding. The company was founded in 2005 and is headquartered in Irvington, NY. | - |
Paul R. Sohmer | M | 75 |
Orthocon, Inc.
![]() Orthocon, Inc. Medical SpecialtiesHealth Technology Orthocon, Inc. designs, develops, and markets medical implantable devices. It provides implantable products designed to stop bone bleeding. The company was founded in 2005 and is headquartered in Irvington, NY. | 3 ans |
Jürg Eckhardt | M | - |
Bellevue Asset Management (Venture Capital)
![]() Bellevue Asset Management (Venture Capital) Investment ManagersFinance Bellevue Asset Management (Venture Capital) is the venture capital arm of Bellevue Asset Management AG, a subsidiary of Bellevue Group AG (SW: BBN) headquartered in Zurich, Switzerland. The firm was founded in 1993. | 12 ans |
Stefan Giesler | M | 57 |
University of Hagen
| 5 ans |
Filmon Zerai | M | - |
Ruprecht-Karls-Universität Heidelberg
| 5 ans |
Jamie Jonas | F | - |
The University of North Carolina at Charlotte
| 1 ans |
Jim Gilliland | M | - |
The University of North Carolina at Charlotte
| 3 ans |
Jochen Müller | M | 58 |
Ruprecht-Karls-Universität Heidelberg
| 3 ans |
Silvia Fazio | M | - |
Ruprecht-Karls-Universität Heidelberg
| 3 ans |
Anika Khan | F | - |
The University of North Carolina at Charlotte
| 1 ans |
Doug Williams | M | - |
The University of North Carolina at Charlotte
| 4 ans |
Gerhard Hütz | M | 66 |
University of Hagen
| 3 ans |
Matthew Michalewicz | M | - |
The University of North Carolina at Charlotte
| 4 ans |
Jürgen Eckhardt | M | 57 |
Bellevue Asset Management (Venture Capital)
![]() Bellevue Asset Management (Venture Capital) Investment ManagersFinance Bellevue Asset Management (Venture Capital) is the venture capital arm of Bellevue Asset Management AG, a subsidiary of Bellevue Group AG (SW: BBN) headquartered in Zurich, Switzerland. The firm was founded in 1993. | 12 ans |
Cory Gossard | M | 50 |
Ruprecht-Karls-Universität Heidelberg
| 4 ans |
Anja Harmeier | M | - |
Pureos Partners AG
![]() Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | 1 ans |
Easter Maynard | F | 53 |
The University of North Carolina at Charlotte
| 2 ans |
Andreas Maderna | M | - |
Ruprecht-Karls-Universität Heidelberg
| 4 ans |
Sandra Albert | F | 47 |
Ruprecht-Karls-Universität Heidelberg
| 6 ans |
Todd Foust | M | - |
The University of North Carolina at Charlotte
| 4 ans |
Andre Kraft | M | 49 |
Ruprecht-Karls-Universität Heidelberg
| 1 ans |
Thomas Neumann | M | - |
University of Hagen
| 5 ans |
Angela Geerling | M | 54 |
Ruprecht-Karls-Universität Heidelberg
| 3 ans |
Kristy Burleigh | F | - |
The University of North Carolina at Charlotte
| 4 ans |
Brandon Lowery | M | - |
The University of North Carolina at Charlotte
| 5 ans |
Karsten Bahlmann | M | - |
Ruprecht-Karls-Universität Heidelberg
| 6 ans |
Ryan Jack | M | - |
The University of North Carolina at Charlotte
| 4 ans |
Francisco Muniz Barreto | M | 53 |
The University of North Carolina at Charlotte
| 1 ans |
Dirk Erich Mausbeck | M | 61 |
University of Hagen
| 6 ans |
Andreas Pfisterer | M | 53 |
University of Hagen
| 1 ans |
Noel Gardner McElreath | M | - |
The University of North Carolina at Charlotte
| 5 ans |
Phil Yates | M | 47 |
The University of North Carolina at Charlotte
| 4 ans |
Jonathan Blanco | M | - |
The University of North Carolina at Charlotte
| 4 ans |
Steffen W. Wurst | M | 65 |
University of Hagen
| 4 ans |
Scott Stevens | M | 51 |
The University of North Carolina at Charlotte
| 4 ans |
Seth A. Richards | M | - |
The University of North Carolina at Charlotte
| 4 ans |
Alison Andreozzi | F | - |
The University of North Carolina at Charlotte
| 4 ans |
Kenneth S. Bring | M | - |
The University of North Carolina at Charlotte
| 1 ans |
Miles Highsmith | M | - |
The University of North Carolina at Charlotte
| 4 ans |
Brian Smyth | M | - |
The University of North Carolina at Charlotte
| 2 ans |
Martin Bürmann | M | 55 |
Ruprecht-Karls-Universität Heidelberg
| 5 ans |
Xiao Hong Han | M | 57 |
Ruprecht-Karls-Universität Heidelberg
| 3 ans |
David Knaack | M | - |
Orthocon, Inc.
![]() Orthocon, Inc. Medical SpecialtiesHealth Technology Orthocon, Inc. designs, develops, and markets medical implantable devices. It provides implantable products designed to stop bone bleeding. The company was founded in 2005 and is headquartered in Irvington, NY. | - |
David Richter | M | - |
Ruprecht-Karls-Universität Heidelberg
| 4 ans |
Harold P. Hope | M | - |
The University of North Carolina at Charlotte
| 4 ans |
Ilinca Rosetti | M | 50 |
Ruprecht-Karls-Universität Heidelberg
| 4 ans |
Marcus Furch | M | 56 |
Ruprecht-Karls-Universität Heidelberg
| 3 ans |
Kelvin Baggett | M | - |
The University of North Carolina at Charlotte
| 5 ans |
Rolf Wiswesser | M | - |
Ruprecht-Karls-Universität Heidelberg
| 5 ans |
Bettina Anders | M | 63 |
University of Hagen
| 2 ans |
Harald F. Stock | M | 56 |
Ruprecht-Karls-Universität Heidelberg
| 3 ans |
Jamie Rizzo | M | - |
The University of North Carolina at Charlotte
| 2 ans |
Lena Thiede | F | - |
Ruprecht-Karls-Universität Heidelberg
| 2 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 35 | 35,00% |
Allemagne | 32 | 32,00% |
Pays-Bas | 21 | 21,00% |
Suisse | 7 | 7,00% |
France | 6 | 6,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Klaus Breiner
- Réseau Personnel